syngenta

Syngenta AG H1 2022 Financial Results Bond Investor presentation

August 30, 2022

Classification: PUBLIC

Cautionary statement regarding forward-looking statements

Some of the statements contained in this document are forward-looking statements. These statements are based on current expectations, assumptions, estimates and projections, and involve known and unknown risks, uncertainties and other factors that may cause results, levels of activity, performance or achievements to be materially different from any forward-looking statements. These statements are generally identified by words or phrases such as "believe", "anticipate", "expect", "intend", "plan", "will", "may", "should", "estimate", "predict", "potential", "continue" or the negative of such terms or other similar expressions. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results and the timing of events may differ materially from the results and/or timing discussed in the forward-looking statements, and you should not place undue reliance on these statements. Syngenta disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the period covered by this document or otherwise.



Syngenta AG H1 2022 Financial Performance


- Sales 24% above last year, 27% at CER
 - CP growth 26%: 14% volume, 15% price & -3% FX
 - Double digit at CER in all regions, esp. Latam & China
 - Seeds growth 14%: 12% volume, 8% price & -6% FX
 - Broad based growth, esp. Corn in Latam and APAC,
 Soybean in the US and Sunflower in Europe
- Gross margin maintained at 2021 level with price increases offsetting increased cost of goods and logistics
- Exc. 2021 Litigation, EBITDA 26% above PY, 31% at CER
- Net income 44% higher exc. 2021 Litigation
- Free cash flow exc. M&A -\$1.15bn vs. -\$0.1bn in 2021;
 - higher volume and cost in inventories and increased receivables from higher sales, partly offset by increased supplier payables; 2021 sale & leaseback disposals; tangible capex broadly flat, higher capitalised development








H1 2022 sales vs. prior year






H1 2022 EBITDA progression vs. prior year



^{*} Price Net is net of cost increases on non-differentiated active ingredient purchases; Other cogs excludes these cost increases




H1 2022 Net Income vs. 2021



^{*} Includes income from associates and non-controlling interests




H1 2022 free cash flow vs. prior year





Change in Net Debt



^{*} EBITDA excluding capitalized development



Working Capital ratios

June 2020	June 2021		June 2022
39%	33%	Trade Working Capital as % of sales (month end)	32%
37%	35%	- Inventories	38%
38%	39%	- Trade Receivables	37%
36%	41%	- Trade Payables	43%
40%	35%	Trade Working Capital as % of sales (average)	29%



2022 Update

- Some commodity prices off their peaks but prices generally remain robust
- Market supply constraints remain
- Market supply risk from potential natural gas shortages
- Further investment in innovation and sustainable agriculture
- Increased Seeds capitalized development costs

- Maintaining sales price discipline
- Price increases to mitigate inflation and higher input costs
- Normal seasonality in free cash generation



